Lipocine Inc.LPCNNASDAQ
Loading
Year-over-year research & development expense growth
5Y CAGR
-11.3%/yr
Long-term compound
Percentile
P71
Within normal range
vs 5Y Ago
0.5x
Contraction
Streak
1 yr
Consecutive growthStable
| Period | Value |
|---|---|
| 2025 | 16.76% |
| 2024 | 0.00% |
| 2023 | 0.00% |
| 2022 | 0.00% |
| 2021 | -100.00% |
| 2020 | 30.53% |
| 2019 | 15.52% |
| 2018 | -41.25% |
| 2017 | 36.26% |
| 2016 | -35.80% |